Experiments have showed that loss of HR proteins such as BRCA1/2 in breast cancer cells stimulate the synthetic lethality of PARG-inhibiting cells, and the PARG inhibitor induces cell death of BRCA mutated or olaparib-resistant breast cancer cells [207]. Here, PARG is linked to breast carcinoma.